Amidst a global pandemic, two biotech companies offer innovative solutions [BioTuesdays]
https://biotuesdays.com/2020/03/31/amidst-a-global-pandemic-two-biotech-companies-offer-innovative-solutions/
Breakthrough lupus drug discovered in Edmonton passes final testing phase [Global News]
https://globalnews.ca/news/6273515/lupus-drug-edmonton-discovery/
Research institute launched out of U of A attracts $25 million in investments [Edmonton Journal]
https://edmontonjournal.com/business/local-business/research-institute-launched-out-of-u-of-a-attracts-25-million-in-investments
Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH [BioTuesdays]
https://www.biotuesdays.com/features/2019/7/30/hepion-pharmaceuticals-ceo-robert-foster-discusses-crv431s-potential-in-nash
Robert Foster swinging for the fence again with Hepion Pharma [BioTuesdays]
http://www.biotuesdays.com/features/2018/11/7/robert-foster-swinging-for-the-fence-again-with-contravir-pharma
TXL for hepatitis B safe, effective in phase 2a study [via Healio]
http://www.healio.com/hepatology/viral-hepatitis/news/online/%7B16ae8488-4b93-459f-94b1-197f2dd77d75%7D/txl-for-hepatitis-b-safe-effective-in-phase-2a-study
An Update on Hepatitis B Therapies [Drug Discovery World]
http://www.ddw-online.com/fall-2016/p315872-an-update-on-hepatitis-b-therapies.html
Dr. Robert Foster, Chief Scientific Officer of Hepion, invited to join the Faculty of Pharmacy & Pharmaceutical Sciences at the University of Alberta as an Honorary Professor
https://hepionpharma.com/wp-content/uploads/2016/07/RTF-Professorship.pdf
